



**BioCryst UK Ltd**  
**Methodological Note**  
**2020**

## Introduction

This methodology note provides guidance on how BioCryst UK Ltd collect and report Transfer of Values made to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs). It represents transfers made by BioCryst in 2020 irrespective of the commencement date of the service. 2020 disclosure report includes all applicable values between 01 January and 31 December 2020.

## Definitions or recipients and Clarifications of Values disclosed

Healthcare Professional (HCP)	Anyone that is a member of the medical, dental, pharmacy or nursing professions and any other professional that may administer, prescribe, purchase, recommend or supply a medicine.
Healthcare Organisation (HCO)	A healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university, or other teaching institution or learned society, or an entity through which an HCP (as defined above) or other relevant decision makers provide a service.
Consultancy	BioCryst engages and compensates HCPs and HCOs to provide expert knowledge derived from their clinical and management experiences and BioCryst may pay an honorarium or a fee based on FMV, and pay reasonable expenses relating to the service provided including travel and accommodation. Transfers of value related to Advisory Board activity and Speakers/Chairs at meetings will be disclosed as 'Fee for service and consultancy'.
Sponsorship	BioCryst supports the continuing medical education of HCPs by covering the costs of registration fees, travel, and accommodation to attend educational events. Both inside and outside the UK. Meals and drinks are not disclosed as per the EFPIA disclosure code.

## Cross boarder payments and Consent for Transfer of Value Reporting

BioCryst UK Ltd collates cross border payments from BioCryst Pharmaceuticals Inc together with all its Affiliates ('BioCryst') and reports the transactions where the recipient has its principal practice in the UK. Per the General Data Protection Regulation (GDPR), financial information such as payments are considered special categories of data and therefore require explicit consent prior to disclosure. BioCryst requested consent for disclosure of this information from HCPs receiving payments. BioCryst included information and details for those HCPs who provided consent to disclose information related to their transfer of value. For HCPs who did not provide consent, their data was reported in an aggregate amount as allowable per ABPI instructions. Consent is not required from Healthcare Organisations (HCOs) in order to disclose transfers of value made to them. Going forward, BioCryst is amending the process of contracting with HCPs by ensuring that consent to post payment

disclosure is obtained at the time of contracting to enable the company to report on an individual basis in most circumstances.

### **Multi-year contracts**

Transfers of value are disclosed according to the date of payment from BioCryst. Only value transferred by BioCryst in 2020 appears in the 2020 disclosure data. For contracts that span more than 1 year, only transfers of value made during year 2020 will be included in the 2020 disclosure. The remainder of the contract values will be disclosed in future disclosure.

### **Currency & VAT**

All disclosed values are in Pound Sterling (GBP). The financial values provided exclude Value Added Tax. Where a payment was fulfilled in another currency the value was converted into Great British Pounds based on the exchange rate at the time of payment.